Coya Therapeutics

COYA

Market cap $123M

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) congratulates our long-standing scientific advisor, Dr. Shimon Sakaguchi, on being awarded the Nobel Prize for his pioneering discovery of regulatory T cells (Tregs) which protect the body from autoimmune diseases. This discovery has reshaped modern immunology and opened new therapeutic frontiers. Dr. Sakaguchi has served as a scientific advisor to Coya guiding strategy to harness and enhance Treg biology for the treatment of seri.

Following the positive interim results in 5 patients announced earlier this year, a total of 9 patients have been enrolled as planned The study is progressing according to protocol, and no safety issues have been reported Study completion is anticipated in Q4 2025 with topline to follow HOUSTON , Sept. 29, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces completion of patient enrollment of an investigator-initiated, proof-of-concept, open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in patients with Frontotemporal Dementia (FTD).

The ALSTARS Trial is a well powered randomized, multi-center, double-blind, placebo-controlled, 24-week  study of COYA 302 in people with Amyotrophic Lateral Sclerosis (ALS) Patients completing the initial 24-week treatment will be invited to participate in a 24-week blinded extension period, during which all participants will receive COYA 302 The ALSTARS Trial will enroll 120 ALS participants at approximately 25 centers in the United States and Canada HOUSTON , Sept. 22, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today the launch of the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS (ClinicalTrials.gov Identifier: NCT 07161999).

COYA 303 is an investigational proprietary combination of LD-IL-2 and GLP-1RA for subcutaneous administration, under development for the treatment of diseases, including Alzheimer's Disease, driven by chronic and sustained inflammation; COYA 303 demonstrated significant attenuation of neuroinflammation in cortex and hippocampus brain regions and upregulation of anti-inflammatory markers, and significant improvement of systemic Treg function and pro-inflammatory cytokines; Results from the first cohort of this in-vivo animal study confirm the previously reported positive findings from in vitro human immune cell systems demonstrating that COYA 303 significantly enhances Treg suppressive function and survival in highly inflammatory microenvironments. HOUSTON , Sept.

NEALS, the world's largest ALS research consortium, has selected the COYA 302 trial and it is now affiliated with NEALS as part of its mission to accelerate the development of new treatments for people living with ALS; Following FDA's recent acceptance of the COYA 302 IND, Coya plans to initiate its Phase 2 study in people with ALS in Q4 2025; The COYA 302 study will be presented during the NEALS Educational Webinar on September 29, 2025. HOUSTON , Sept.

Q&A Highlights FDA IND Clearance, Partnerships, and 2025 Milestones Across ALS and Neurodegeneration Programs NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView today published a Q&A feature with Arun Swaminathan, Chief Executive Officer of Coya Therapeutics, Inc. (“Coya” or the “Company”) (NASDAQ: COYA), a clinical-stage biotechnology company developing Treg-modulating therapies to address ALS and other neurodegenerative diseases.

HOUSTON , Sept. 3, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the company's management team will participate in two upcoming investor conferences this month.

Coya Therapeutics, Inc. (COYA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, COYA's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

FDA acceptance enables initiation of a Phase 2 multicenter, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of COYA 302 in patients with ALS HOUSTON , Aug. 25, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces that the U.S. Food and Drug Administration ("FDA" or the "Agency") has accepted its Investigational New Drug (IND) application for COYA 302. This proprietary immunomodulatory biologic combination therapy is being developed for the treatment of patients with amyotrophic lateral sclerosis (ALS).

Coya Therapeutics, Inc. (COYA) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.19 per share a year ago.